Maravai LifeSciences Holdings Inc (Class A)
Closed
SectorHealthcare
4.81 1.26
Overview
Share price change
24h
Min
4.6899999999999995
Max
4.87
Income | 36M -3.7M |
|---|---|
Sales | 16M 66M |
EPS | 0.01 |
Profit margin | -5.67 |
Employees | 416 |
EBITDA | 57M 15M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +18.13% upside |
Next Earnings | 10 Aug 2026 |
|---|
Market Cap | 225M 1.6B |
|---|---|
Previous open | 3.55 |
Previous close | 4.81 |
Maravai LifeSciences Holdings Inc (Class A) Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Maravai LifeSciences Holdings Inc (Class A) Forecast
Price Target
By TipRanks
18.13% upside
12 Months Forecast
Average 5.67 USD 18.13%
High 6 USD
Low 5 USD
Based on 5 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Maravai LifeSciences Holdings Inc (Class A)
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
